Clinical Trials Logo

Cholangiocarcinoma clinical trials

View clinical trials related to Cholangiocarcinoma.

Filter by:

NCT ID: NCT04480190 Withdrawn - Cholangiocarcinoma Clinical Trials

Neoadjuvant Therapy in Biliary Adenocarcinoma

Start date: February 4, 2021
Phase: Phase 1
Study type: Interventional

Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.

NCT ID: NCT04479904 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Start date: August 10, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, multi-center Phase II clinical trial intended to observe and evaluate the efficacy and safety of famitinib malate in treating iCCA(Intrahepatic Cholangiocarcinoma ) patients with FGFR2 genetic aberrations who failed first-line therapy.

NCT ID: NCT04404647 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Irreversible Electroporation of Unresectable Liver Tumors

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.

NCT ID: NCT03801499 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lenvatinib for patients with unresectable intrahepatic cholangiocarcinoma

NCT ID: NCT03563352 Withdrawn - Cholangiocarcinoma Clinical Trials

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

Start date: August 30, 2018
Phase:
Study type: Observational

This trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer. Learning what participants like and dislike about their current or past used nutritional supplements may help doctor know how to improve them.

NCT ID: NCT03117855 Withdrawn - Clinical trials for Stage III Intrahepatic Cholangiocarcinoma

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Start date: December 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of capecitabine and Y-90 radioembolization in treating patients with bile duct cancer in the liver that has spread to other places in the body and cannot be removed by surgery. Radiation therapy, such as Y-90 radioembolization, injects tiny radioactive Y-90 microspheres into the blood supply next to the liver tumors to kill tumor cells. Capecitabine may make radiation more effective. Giving capecitabine and Y-90 radioembolization may work better in treating patients with bile duct cancer in the liver.

NCT ID: NCT03081039 Withdrawn - Clinical trials for Intrahepatic Cholangiocarcinoma

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

Start date: August 21, 2017
Phase: Phase 3
Study type: Interventional

Compare the efficacy of adjuvant chemotherapy with Cisplatin or Carboplatin and Gemcitabine versus Gemcitabine in patients with resected or ablated intra-hepatic cholangiocarcinoma.

NCT ID: NCT02856568 Withdrawn - Clinical trials for Unresectable Extrahepatic Bile Duct Carcinoma

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of ricolinostat when given together with gemcitabine hydrochloride and cisplatin in treating patients with cholangiocarcinoma that cannot be removed by surgery or has spread to other places in the body. Ricolinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ricolinostat together with gemcitabine hydrochloride and cisplatin may work better in treating patients with cholangiocarcinoma that cannot be removed by surgery or has spread to other places.

NCT ID: NCT02174575 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery

Start date: July 2014
Phase: Phase 4
Study type: Interventional

- It has been shown that patients who undergo liver resection surgery are at high risk for postoperative acute kidney injury (AKI). - Sevoflurane may increase the risk for postoperative AKI because of production of compound-A. - Therefore, we have planned to investigate the effects of different anesthetic agents on postoperative renal function. - Patients undergoing liver resection surgery are randomized into 2 groups. - One of the groups receives sevoflurane and the other group receives desflurane. - Blood and urine specimen are sampled both pre- and postoperatively, and several biomarkers are compared between the groups.

NCT ID: NCT02106871 Withdrawn - Pancreatic Cancer Clinical Trials

Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer

PCC
Start date: April 2014
Phase: Phase 1
Study type: Interventional

Investigation of the effects of daily sildenafil on patients with pancreatic or cholangiocarcinoma cancer undergoing treatment.